MedPath

The relationship between anti-Xa activity and the renal function in elderly patients who are on apixaba

Not Applicable
Conditions
atrial fibrillation
Registration Number
JPRN-UMIN000020692
Lead Sponsor
Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Patients contraindicated for apixaban (1)Patients with a history of a hypersensitivity to the ingredients of apixaban (2)Patients with bleeding symptoms which can be of a clinical concern within 6 months (e.g., active gastric ulcers, platelets < 100000, hemoglobin < 10 g/dL, and s stroke within 10 days) (3)Patients with blood clotting defects and liver disease with a clinically important bleeding risk (4)Patients with renal failure (creatinine clearance < 15 mL/min) Severe liver dysfunction (AST and ALT of > 2-fold the upper limits of normal (ULN) and a total bilirubin of > 1.5-fold the ULN) Patients with valvular disorders requiring surgery Patients who cannot orally take drugs or visit the Outpatient Unit on a regular basis Patients with a prognosis of < one year Patients anticoagulated with heparin or enoxaparin

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath